HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Silvano Ferrini Selected Research

Activated-Leukocyte Cell Adhesion Molecule (Neurolin)

1/2019ALCAM Mediates DC Migration Through Afferent Lymphatics and Promotes Allospecific Immune Reactions.
10/2013Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.
6/2013Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors.
2/2011Activated leukocyte cell adhesion molecule expression and shedding in thyroid tumors.
3/2010Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.
1/2010Different subcellular localization of ALCAM molecules in neuroblastoma: Association with relapse.
3/2008Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
12/2007The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells.
4/2005Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Silvano Ferrini Research Topics

Disease

61Neoplasms (Cancer)
11/2021 - 03/2002
15Neuroblastoma
01/2018 - 02/2003
12Carcinoma (Carcinomatosis)
01/2012 - 04/2002
9Ovarian Epithelial Carcinoma
02/2020 - 12/2007
6Adenocarcinoma
07/2009 - 07/2002
5Neoplasm Metastasis (Metastasis)
01/2017 - 09/2006
4Ovarian Neoplasms (Ovarian Cancer)
02/2020 - 09/2004
4Melanoma (Melanoma, Malignant)
06/2019 - 01/2012
4Uveal melanoma
06/2019 - 01/2012
4B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2015 - 05/2006
4Lymphoma (Lymphomas)
01/2015 - 12/2005
3Ascites
02/2020 - 06/2013
3Carcinogenesis
08/2017 - 02/2005
3Lung Neoplasms (Lung Cancer)
12/2015 - 09/2008
3Kidney Neoplasms (Kidney Cancer)
02/2013 - 02/2009
2Inflammation (Inflammations)
08/2021 - 02/2011
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
10/2017 - 07/2003
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2015 - 08/2009
2Glioblastoma (Glioblastoma Multiforme)
01/2011 - 10/2007
2Glioma (Gliomas)
01/2011 - 10/2007
1Pleural Effusion (Pleural Effusions)
11/2021
1Malignant Mesothelioma
11/2021
1Mesothelioma
08/2021
1Corneal Diseases (Corneal Disease)
01/2019
1Anemia
08/2017
1Monosomy
01/2017
1Eye Neoplasms (Eye Cancer)
01/2017
1Cardiovascular Diseases (Cardiovascular Disease)
01/2016
1Shock
06/2015

Drug/Important Bio-Agent (IBA)

16CytokinesIBA
08/2021 - 03/2002
11Proteins (Proteins, Gene)FDA Link
02/2020 - 03/2002
10AntibodiesIBA
10/2017 - 02/2005
10Interleukin-15 (Interleukin 15)IBA
02/2013 - 07/2002
9Activated-Leukocyte Cell Adhesion Molecule (Neurolin)IBA
01/2019 - 04/2005
9interleukin-21 (interleukin 21)IBA
01/2015 - 02/2004
8Messenger RNA (mRNA)IBA
01/2015 - 04/2002
8VaccinesIBA
05/2014 - 06/2004
7InterleukinsIBA
09/2011 - 06/2004
7Interleukin-12 (IL 12)IBA
07/2009 - 07/2002
6Interleukin-27 (Interleukin 27)IBA
08/2021 - 12/2015
6Biological ProductsIBA
01/2017 - 04/2002
6Interleukin-18 (Interleukin 18)IBA
12/2015 - 04/2002
5Protein Isoforms (Isoforms)IBA
06/2015 - 03/2002
5Interleukin-2 (IL2)IBA
05/2010 - 03/2002
4Biomarkers (Surrogate Marker)IBA
11/2021 - 09/2011
4Monoclonal AntibodiesIBA
10/2017 - 12/2005
4Metalloproteases (Metalloproteinases)IBA
11/2014 - 12/2007
4Interferon-gamma (Interferon, gamma)IBA
05/2010 - 03/2002
4AntigensIBA
11/2008 - 06/2004
3Interleukin-6 (Interleukin 6)IBA
08/2021 - 07/2009
3Therapeutic UsesIBA
12/2015 - 01/2005
3ArginaseIBA
01/2015 - 09/2008
3ChemokinesIBA
07/2011 - 07/2002
3Complement System Proteins (Complement)IBA
01/2011 - 12/2005
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2009 - 07/2002
2InterferonsIBA
11/2021 - 01/2007
2Carrier Proteins (Binding Protein)IBA
02/2020 - 05/2010
2Tyrosine (L-Tyrosine)FDA Link
02/2020 - 09/2008
2Oncogene Proteins (Oncogene Protein)IBA
06/2019 - 09/2015
2MicroRNAs (MicroRNA)IBA
08/2017 - 01/2015
2Histocompatibility Antigens Class IIBA
11/2016 - 11/2007
2EnzymesIBA
09/2015 - 09/2006
2Conditioned Culture MediaIBA
09/2015 - 02/2011
2ErbB Receptors (EGF Receptor)IBA
06/2015 - 02/2003
2Interleukin-10 (Interleukin 10)IBA
01/2015 - 01/2015
2ferumoxtran-10 (ultrasmall superparamagnetic iron oxide)IBA
06/2010 - 03/2008
2Surface Antigens (Surface Antigen)IBA
06/2010 - 12/2005
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2010 - 09/2006
2Immunoglobulin G (IgG)IBA
10/2007 - 07/2003
2DNA (Deoxyribonucleic Acid)IBA
01/2007 - 02/2005
2Caspase 8 (Caspase-8)IBA
01/2007 - 12/2004
2MHC class II transactivator proteinIBA
06/2006 - 05/2003
2Histocompatibility Antigens Class IIIBA
06/2006 - 05/2003
1AsbestosIBA
08/2021
1LuciferasesIBA
06/2020
1Tyrosine Kinase InhibitorsIBA
01/2018
1ponatinibIBA
01/2018
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
08/2017
1Blood Group Antigens (Blood Groups)IBA
08/2017
1Heme (Haem)IBA
08/2017
1PorphyrinsIBA
08/2017
1RNA Splicing FactorsIBA
01/2017
1Immune Checkpoint InhibitorsIBA
01/2017
1LigandsIBA
01/2016
1Anti-Inflammatory Agents (Anti-Inflammatories)IBA
01/2016
1Glycoproteins (Glycoprotein)IBA
09/2015
1ImmunosorbentsIBA
09/2015
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
09/2015
1AfatinibIBA
06/2015
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
06/2015
1Epithelial Cell Adhesion MoleculeIBA
06/2015
1Cisplatin (Platino)FDA LinkGeneric
06/2015
1InflammasomesIBA
04/2015

Therapy/Procedure

18Immunotherapy
10/2017 - 02/2006
15Therapeutics
11/2021 - 01/2005
2Radiotherapy
01/2017 - 01/2011
2Drug Therapy (Chemotherapy)
01/2011 - 02/2003
1Aftercare (After-Treatment)
09/2015
1Combination Drug Therapy (Combination Chemotherapy)
06/2015
1Combined Modality Therapy
01/2015